[1]吴建伟.阿奇霉素联合头孢类药物在慢性阻塞性肺疾病急性加重期抗感染治疗中的疗效[J].医学信息,2022,35(13):127-129.[doi:10.3969/j.issn.1006-1959.2022.13.029]
　WU Jian-wei.Effect of Azithromycin Combined with Cephalosporins in Anti-infection Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease[J].Medical Information,2022,35(13):127-129.[doi:10.3969/j.issn.1006-1959.2022.13.029]
点击复制

阿奇霉素联合头孢类药物在慢性阻塞性肺疾病急性加重期抗感染治疗中的疗效()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年13期
页码:
127-129
栏目:
论著
出版日期:
2022-07-01

文章信息/Info

Title:
Effect of Azithromycin Combined with Cephalosporins in Anti-infection Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease
文章编号:
1006-1959（2022）13-0127-03
作者:
吴建伟
（天津市宝坻区中医医院药剂科，天津 301800）
Author(s):
WU Jian-wei
(Department of Pharmacy,Tianjin Baodi District Traditional Chinese Medicine Hospital,Tianjin 301800,China)
关键词:
阿奇霉素; 慢性阻塞性肺疾病; 肺功能
Keywords:
zithromycin; Chronic obstructive pulmonary disease; Pulmonary function
分类号:
R563
DOI:
10.3969/j.issn.1006-1959.2022.13.029
文献标志码:
A
摘要:
目的 研究阿奇霉素联合头孢类药物在慢性阻塞性肺疾病急性加重期抗感染治疗中的疗效。方法 选取2020年4月-2021年4月天津市宝坻区中医医院诊治的76例慢性阻塞性肺疾病急性加重期患者为研究对象，采用随机数字表法分为对照组和观察组，各38例。对照组采用头孢类药物治疗，观察组在对照组基础上给予阿奇霉素治疗，比较两组临床治疗疗效、肺功能指标[第1秒用力呼气容积/用力肺活量（FEV1/FVC）、最大呼气速度（PEF）]、临床症状评分、IgG抗体滴度以及临床不良反应发生情况。结果 观察组治疗总有效率为94.74%，高于对照组的81.58%（P＜0.05）；观察组FEV1/FVC、PEF大于对照组（P＜0.05）；观察组呼吸困难、咳嗽、气喘临床症状评分低于对照组（P＜0.05）；观察组IgG抗体滴度低于对照组（P＜0.05）；观察组不良反应总发生率与对照组比较，差异无统计学意义（P＞0.05）。结论 阿奇霉素联合头孢类药物抗感染治疗慢性阻塞性肺疾病急性加重期效果确切，可改善肺功能，缓解临床症状，降低IgG抗体滴度，且不增加不良反应发生几率，安全性较高。
Abstract:
Objective To study the efficacy of azithromycin combined with cephalosporins in the anti-infective treatment of acute exacerbation of chronic obstructive pulmonary disease.Methods A total of 76 patients with acute exacerbation of chronic obstructive pulmonary disease in Tianjin Baodi District Traditional Chinese Medicine Hospital from April 2020 to April 2021 were selected and randomly divided into control group and observation group, with 38 cases in each group. The control group was treated with cephalosporins, and the observation group was treated with azithromycin on the basis of the control group. The clinical therapeutic efficacy, lung function indexes [forced expiratory volume in one second/forced vital capacity (FEV1/FVC), maximum expiratory velocity (PEF)], clinical symptom score, IgG antibody titer and clinical adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 94.74%, which was higher than 81.58% of the control group (P<0.05). FEV1/FVC and PEF in the observation group were higher than those in the control group (P<0.05). The clinical symptom scores of dyspnea, cough and asthma in the observation group were lower than those in the control group (P<0.05). The IgG antibody titer of the observation group was lower than that of the control group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the observation group and the control group (P>0.05).Conclusion Azithromycin combined with cephalosporins is effective in the treatment of acute exacerbation of chronic obstructive pulmonary disease, which can improve lung function, relieve clinical symptoms, reduce IgG antibody titer, and do not increase the incidence of adverse reactions, with high safety.

参考文献/References:

[1]宫姝宁,武彩风,张玲燕.哮喘-慢性阻塞性肺疾病重叠综合征与慢性阻塞性肺疾病治疗前后临床特征比较[J].山西医药杂志,2021,50(5):762-764.[2]刘平平.头孢唑肟钠与阿奇霉素联用对慢阻肺急性加重期患者的临床疗效及其对肺功能的影响[J].抗感染药学,2020,17(2):302-304.[3]胡厚军,李秀媚.乌苯美司联合沙美特罗替卡松治疗慢性阻塞性 肺疾病急性加重期临床研究[J].中国药业,2019,28(20):57-59.[4]李宝亮,佟平丽.阿奇霉素与头孢地嗪钠联合使用对肺部感染患者临床症状与炎症状态的改善效果[J].湖南师范大学学报(医学版),2018,15(3):146-149.[5]蒋亚林,荣令,唐超,等.比较阿奇霉素与罗红霉素在预防慢性阻塞性肺疾病急性加重中的作用及不良反应[J].国际呼吸杂志,2018,38(16):1220-1224.[6]周诗晶,彭娟,曹国军,等.老年慢性阻塞性肺疾病急性发作期患者的病原菌及耐药性研究[J].巴楚医学,2018,1(3):34-38.[7]王宁.小剂量阿奇霉素对老年COPD稳定期肺功能和炎性因子的影响[J].黑龙江医药,2018,31(5):63-64.[8]中华人民共和国卫生部.慢性阻塞性肺疾病诊断标准[J].国际呼吸杂志,2011,31(1):1-2.[9]詹六英.阿奇霉素与头孢唑肟联用对慢性阻塞性肺疾病急性加重患者抗感染治疗的疗效及其对肺功能的影响[J].抗感染药学,2020,17(1):107-109.[10]周木阳,许鲁宁.阿奇霉素联合头孢噻肟钠治疗慢性阻塞性肺疾病疗效观察[J].临床合理用药杂志,2018,11(28):63-64.[11]胡克增,陈汉才,陈辉,等.阿奇霉素联合头孢类药物在慢性阻塞性肺疾病急性加重期抗感染治疗中的疗效[J].中华医院感染学杂志,2018,28(3):360-363. [12]马丽,仲光.血清降钙素原测定对合理应用抗菌药物治疗老年慢性阻塞性肺疾病急性加重期的指导价值[J].中华老年多器官疾病杂志,2016,15(10):780-783.[13]王娟,林忠.阿奇霉素联合头孢类药物治疗慢性阻塞性肺疾病急性加重期的效果观察[J].中外医学研究,2017,15(33):181-182.[14]李红梅.阿奇霉素联合阿司匹林治疗慢性阻塞性肺疾病急性加重期患者的临床效果[J].包头医学院学报,2018,34(9):50-51. [15]韩玲.阿奇霉素联合头孢类药物治疗慢性阻塞性肺疾病急性加重期的疗效及药学分析[J].医学信息,2016,29(23):45-46. [16]何丽萍,周娜.阿奇霉素联合头孢类药物治疗慢性阻塞性肺疾病急性加重期的药学分析[J].国际医药卫生导报,2018,24(2):251-252.[17]石卫霞,林英翔,朱建国,等.慢性阻塞性肺疾病急性加重期患者继发真菌感染的危险因素分析[J].中国医药,2016,11(1):34-37.[18]于涛,祝杨.急性加重期慢性阻塞性肺疾病患者感染呼吸道病毒特征及与炎性细胞因子关联分析[J].中国医师进修杂志,2019,42(9):786-790.[19]董辉航.阿奇霉素配合头孢噻肟钠治疗慢性阻塞性肺疾病患者的价值[J].山西医药杂志,2019,48(21):2628-2630.[20]赖国明.头孢哌酮-舒巴坦与阿奇霉素联用对慢性阻塞性肺疾病患者伴下呼吸道感染的临床疗效评价[J].抗感染药学,2018,68(3):79-80.

相似文献/References:

[1]钟雪梅,李 黎,米热班·热夏提,等.α1-抗胰蛋白酶与维吾尔族慢性阻塞性肺疾病的相关性分析[J].医学信息,2018,31(02):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
　ZHONG Xue-mei,LI Li,Mirban·rixat,et al.Correlation Analysis of α1-antitrypsin and Uygur Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(13):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
[2]陈文福.噻托溴铵治疗稳定期慢性阻塞性肺疾病的临床疗效分析[J].医学信息,2018,31(02):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
　CHEN Wen-fu.Clinical Analysis of Tiotropium Bromide in the Treatment of Stable Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(13):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
[3]吴仲东.无创机械通气用于COPD合并呼吸衰竭的疗效分析[J].医学信息,2018,31(04):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
　WU Zhong-dong.Clinical Analysis of Noninvasive Mechanical Ventilation in Patients with COPD Complicated with Respiratory Failure[J].Medical Information,2018,31(13):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
[4]龙有珠.氨茶碱联合呼吸功能训练治疗慢性阻塞性肺疾病的疗效分析[J].医学信息,2018,31(04):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
　LONG You-zhu.Effect of Aminophylline Combined with Respiratory Function Training on Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(13):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
[5]皮鑫鑫,邓 革.临床药师对1例院内感染患者的病例分析[J].医学信息,2018,31(04):188.[doi:10.3969/j.issn.1006-1959.2018.04.072]
[6]赵俊芝,赵永强,梁 曼.甲泼尼龙联合阿奇霉素治疗难治性支原体肺炎患儿的 临床效果分析[J].医学信息,2018,31(07):131.[doi:10.3969/j.issn.1006-1959.2018.07.044]
　ZHAO Jun-zhi,ZHAO Yong-qiang,LIANG Man.Analysis of the Clinical Effect of Methylprednisolone Combined with Azithromycin in Treatment of Children with Refractory Mycoplasma Pneumonia[J].Medical Information,2018,31(13):131.[doi:10.3969/j.issn.1006-1959.2018.07.044]
[7]罗 倩.COPD加重期患者肺功能、血气指标及 炎症指标的变化分析[J].医学信息,2018,31(09):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
　LUO Qian.Changes of Pulmonary Function,Blood Gas and Inflammation in Patients with COPD Exacerbation[J].Medical Information,2018,31(13):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
[8]赵志国.有创-无创序贯通气疗法治疗慢性阻塞性肺疾病 引发的严重呼吸衰竭的临床研究[J].医学信息,2018,31(11):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
　ZHAO Zhi-guo.Clinical Study of Invasive Non-invasive Sequential Ventilation in Treatment of Severe Respiratory Failure Caused by Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(13):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
[9]金彦青.NPPV治疗慢性阻塞性肺疾病合并 重症呼吸衰竭的临床疗效观察[J].医学信息,2018,31(14):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
　JIN Yan-qing.Clinical Efficacy of NPPV in the Treatment of Chronic Obstructive Pulmonary Disease with Severe Respiratory Failure[J].Medical Information,2018,31(13):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
[10]何冬兰,李 文.NLR、PLR在慢性阻塞性肺疾病进展、预后中的相关研究[J].医学信息,2022,35(11):25.[doi:10.3969/j.issn.1006-1959.2022.11.008]
　HE Dong-lan,LI Wen.Study on Correlation Between NLR and PLR in the Progression and Prognosis of Chronic Obstructive Pulmonary Disease[J].Medical Information,2022,35(13):25.[doi:10.3969/j.issn.1006-1959.2022.11.008]

更新日期/Last Update: 1900-01-01